...
search icon
anik-img

Anika Therapeutics Inc, Common Stock

ANIK

NSQ

$17.86

+$0.21

(1.19%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$261.57M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
32.05K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.86
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$15.4 L
$29.11 H
$17.86

About Anika Therapeutics Inc, Common Stock

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameANIKSectorS&P500
1-Week Return0.39%-0.03%1.53%
1-Month Return14.63%4.56%4.75%
3-Month Return5.06%1.29%2.77%
6-Month Return-29.38%-3.54%12.18%
1-Year Return-24.29%1.59%22.34%
3-Year Return-40.98%13.55%38.91%
5-Year Return-56.94%40.85%80.7%
10-Year Return-57.88%105.52%190.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue114.61M130.46M147.79M156.24M166.66M[{"date":"2019-12-31","value":68.77,"profit":true},{"date":"2020-12-31","value":78.28,"profit":true},{"date":"2021-12-31","value":88.68,"profit":true},{"date":"2022-12-31","value":93.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue28.75M61.43M64.85M62.66M63.57M[{"date":"2019-12-31","value":44.33,"profit":true},{"date":"2020-12-31","value":94.73,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.62,"profit":true},{"date":"2023-12-31","value":98.03,"profit":true}]
Gross Profit85.86M69.03M82.94M93.58M103.09M[{"date":"2019-12-31","value":83.29,"profit":true},{"date":"2020-12-31","value":66.96,"profit":true},{"date":"2021-12-31","value":80.46,"profit":true},{"date":"2022-12-31","value":90.77,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin74.92%52.91%56.12%59.89%61.85%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":70.63,"profit":true},{"date":"2021-12-31","value":74.91,"profit":true},{"date":"2022-12-31","value":79.95,"profit":true},{"date":"2023-12-31","value":82.56,"profit":true}]
Operating Expenses51.62M83.49M101.42M112.98M191.47M[{"date":"2019-12-31","value":26.96,"profit":true},{"date":"2020-12-31","value":43.61,"profit":true},{"date":"2021-12-31","value":52.97,"profit":true},{"date":"2022-12-31","value":59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income34.25M(14.47M)(18.48M)(19.40M)(87.64M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-42.24,"profit":false},{"date":"2021-12-31","value":-53.96,"profit":false},{"date":"2022-12-31","value":-56.65,"profit":false},{"date":"2023-12-31","value":-255.9,"profit":false}]
Total Non-Operating Income/Expense3.75M(604.00K)(376.00K)1.31M4.32M[{"date":"2019-12-31","value":86.65,"profit":true},{"date":"2020-12-31","value":-13.97,"profit":false},{"date":"2021-12-31","value":-8.7,"profit":false},{"date":"2022-12-31","value":30.26,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income36.12M(28.62M)2.43M(18.75M)(85.33M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-79.24,"profit":false},{"date":"2021-12-31","value":6.72,"profit":true},{"date":"2022-12-31","value":-51.9,"profit":false},{"date":"2023-12-31","value":-236.23,"profit":false}]
Income Taxes8.93M(4.64M)(1.71M)(3.89M)(2.66M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-51.99,"profit":false},{"date":"2021-12-31","value":-19.12,"profit":false},{"date":"2022-12-31","value":-43.54,"profit":false},{"date":"2023-12-31","value":-29.79,"profit":false}]
Income After Taxes27.19M(23.98M)4.13M(14.86M)(82.67M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-88.19,"profit":false},{"date":"2021-12-31","value":15.2,"profit":true},{"date":"2022-12-31","value":-54.64,"profit":false},{"date":"2023-12-31","value":-304,"profit":false}]
Income From Continuous Operations27.19M(23.98M)4.13M(14.86M)(24.57M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-88.19,"profit":false},{"date":"2021-12-31","value":15.2,"profit":true},{"date":"2022-12-31","value":-54.64,"profit":false},{"date":"2023-12-31","value":-90.37,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income27.19M(23.98M)4.13M(14.86M)(82.67M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-88.19,"profit":false},{"date":"2021-12-31","value":15.2,"profit":true},{"date":"2022-12-31","value":-54.64,"profit":false},{"date":"2023-12-31","value":-304,"profit":false}]
EPS (Diluted)2.06(0.64)0.29(0.89)(5.41)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-31.07,"profit":false},{"date":"2021-12-31","value":14.08,"profit":true},{"date":"2022-12-31","value":-43.2,"profit":false},{"date":"2023-12-31","value":-262.62,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ANIK
Cash Ratio 2.45
Current Ratio 5.34
Quick Ratio 3.78

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ANIK
ROA (LTM) -4.01%
ROE (LTM) -43.31%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ANIK
Debt Ratio Lower is generally better. Negative is bad. 0.22
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.78

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ANIK
Trailing PE NM
Forward PE 38.02
P/S (TTM) 1.59
P/B 1.45
Price/FCF 69
EV/R 1.38
EV/Ebitda NM
PEG 3.75

FAQs

What is Anika Therapeutics Inc share price today?

Anika Therapeutics Inc (ANIK) share price today is $17.86

Can Indians buy Anika Therapeutics Inc shares?

Yes, Indians can buy shares of Anika Therapeutics Inc (ANIK) on Vested. To buy Anika Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ANIK stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Anika Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Anika Therapeutics Inc (ANIK) via the Vested app. You can start investing in Anika Therapeutics Inc (ANIK) with a minimum investment of $1.

How to invest in Anika Therapeutics Inc shares from India?

You can invest in shares of Anika Therapeutics Inc (ANIK) via Vested in three simple steps:

  • Click on Sign Up or Invest in ANIK stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Anika Therapeutics Inc shares
What is Anika Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Anika Therapeutics Inc (ANIK) is $29.11. The 52-week low price of Anika Therapeutics Inc (ANIK) is $15.4.

What is Anika Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Anika Therapeutics Inc (ANIK) is 1.45

What is the Market Cap of Anika Therapeutics Inc?

The market capitalization of Anika Therapeutics Inc (ANIK) is $261.57M

What is Anika Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Anika Therapeutics Inc is ANIK

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top